Evidence map›Paper›PMID 40239103›Full record

ArticleJournal of the American Chemical Society2025

Mechanistic Investigations into the Olefination of Oximes and Hydrazones Support Intermediate Ruthenium Nitrides.

Jacob R Ludwig, John J Kiernicki, Daniel J Nasrallah, Troy E Zehnder, Matthias Zeller, Nathaniel K Szymczak, Corinna S Schindler

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jacob R LudwigResearch and Development, Abbvie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States.ORCID 0000-0001-8160-8736
John J KiernickiDepartment of Chemistry, Drury University, 900 North Benton Ave, Springfield, Missouri 65802, United States.ORCID 0000-0002-6240-5156
Daniel J NasrallahDepartment of Chemistry, Roanoke College, 221 College Ln, Salem, Virginia 24153, United States.ORCID 0000-0001-8010-6953
Troy E ZehnderDepartment of Chemistry, University of Michigan, 930 N University Ave, Ann Arbor, Michigan 48109, United States.
Matthias ZellerH.C. Brown Laboratory, Department of Chemistry, Purdue University, 560 Oval Dr., West Lafayette, Indiana 47907, United States.ORCID 0000-0002-3305-852X
Nathaniel K SzymczakDepartment of Chemistry, University of Michigan, 930 N University Ave, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-1296-1445
Corinna S SchindlerDepartment of Chemistry, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada.ORCID 0000-0003-4968-8013

Funding

The Role of Secondary Interactions Relevant to Biological Reductions of Small MoleculesR35GM136360 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Nathaniel Kolnik Szymczak · 2020 to 2026
$2.5M
NIGMS NIH HHS R35 GM136360
6 · The paper itself

Abstract

The olefination of oximes and hydrazones with ruthenium alkylidenes has recently been developed by matching substrate/metal orbital energy and polarization. We herein report detailed mechanistic investigations showing that the reaction pathway is distinct from previously established olefin-olefin metathesis reactions. The ruthenium alkylidene-mediated metathesis of olefins and hydrazones or oximes proceeds via a pathway that form intermediate ruthenium nitrides, which undergo subsequent bimolecular extrusion of molecular nitrogen. Detailed insights into the controlling features of this transformation presented herein are key to the development of future catalytic protocols for the olefination of oximes and hydrazones.

Identifiers

PMID40239103
PMCPMC12065548

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.